Metabolic Syndrome


Basic disorders of the metabolic syndrome are obesity (especially the central type), dyslipidemia.

Disorders is the presence of a resistance of peripheral tissues, especially muscle tissue, the action of insulin. This insulin resistance is not a disease, but the central metabolic disorder, polycystic ovarian syndrome, increased coagulability of blood etc,

The metabolic syndrome is a jigsaw of metabolic disorders which inevitably lead to atherosclerosis and cardiovascular disease. Basic tiles of this puzzle are obesity (especially the central type), dyslipidemia,  disorders is the presence of a resistance of peripheral tissues (mainly muscle) to the action of insulin. This insulin resistance is not a disease, but it is central metabolic disorder that increases the risk of disorders that constitute the metabolic syndrome, while causally associated with these disorders. Today, other basic components of the metabolic  fatty liver, sleep apnea, polycystic ovarian syndrome, increased coagulability of blood etc

These disorders are certainly not define metabolic syndrome, however, associated with it, because of their common metabolic reference, which is insulin resistance.

Metabolic syndrome occurs when genetically susceptible individuals become overweight, In this way, factors such as unhealthy diet and reduced or no physical activity form a “toxic” environment that rapidly increases the incidence of the metabolic syndrome. 25% of the population in America is already estimated to exhibit metabolic syndrome. In diabetes, the prevalence of metabolic syndrome reaches 92%.

There are various proposals documentary metabolic syndrome by large organizations: WHO (World Health Organization), NCEP- ATP III (Special American Commission).

Clinical classification of metabolic syndrome, which has been proposed by US special committee (NCER) three years ago, mainly applies since, because it allows easy identification in the clinical practice of the metabolic syndrome.

However, recently various classifications associated with different approaches to metabolic “triggers” metabolic syndrome. The WHO approach essentially sees the root cause of insulin resistance leading to lipolysis and lipotoxikotita,

This approach considers the NCEP abdominal obesity baseline cause of metabolic syndrome, and the large abdominal cell secretes cytokines, particularly TNF protein which acts on the insulin receptor and contributes to the establishment of insulin resistance. Additionally, the increased release of fatty acids for abdominal obesity leads, on the one hand, to increased triglyceride synthesis and, secondly, to an increased synthesis of specific athiromatogonon molecules (small dense LDL) and decrease the protective cholesterol (HDL). These two approaches lead and create two entities, both of which prospers the atheromatous process: diabetes with metabolic syndrome and metabolic syndrome without diabetes.

The parameters of the metabolic syndrome with the auxiliary support in insulin resistance in disease in metabolic syndrome.

Recent studies indicate that the metabolic syndrome is associated with four times the risk of coronary death while other studies show a doubling of CHD risk when the presence of diabetes.

The treatment of the metabolic syndrome include improving basic underlying metabolic disorder, i.e., the resistance of peripheral tissues to the action of insulin, this may be achieved by a change in lifestyle (decrease in body weight and moderate daily physical activity) and possibly with drugs ( eg glitazones) and the control of risk factors coexist (hypertension, dyslipidemia, mainly reduction of LDL, diabetes), the diet is a key contributor to the metabolic syndrome treatment, after hypothermic diets reduce body weight, blood pressure and improve lipid profile and glycemic control. Reduction of 5-7% of the initial weight in obese is able to significantly improve all aspects of the metabolic syndrome.